In a recent issue of Nature Medicine, researchers associated with Axial Therapeutics reported first preliminary clinical trial evidence that AB-2004, a first-in-class molecular therapeutic that prevents the absorption of neuroactive microbial metabolites from the GI tract, can help improve ASD-associated behaviors.
In this and a companion article by Needham et al., the group also describe preclinical studies in mouse models that provide a rationale for taking this therapeutic approach into the clinic.
To read a summary and editorial of these two articles by Rochellys Diaz Heijtz, click here https://www.nature.com/articles/s41591-022-01711-8